Literature DB >> 32404004

PKC (Protein Kinase C)-δ Modulates AT (Antithrombin) Signaling in Vascular Endothelial Cells.

Sumith R Panicker1, Indranil Biswas1, Hemant Giri1, Xiaofeng Cai1, Alireza R Rezaie1,2.   

Abstract

OBJECTIVE: Native and latent conformers of AT (antithrombin) induce anti-inflammatory and proapoptotic signaling activities, respectively, in vascular endothelial cells by unknown mechanisms. Synd-4 (syndecan-4) has been identified as a receptor that is involved in transmitting signaling activities of AT in endothelial cells. Approach and
Results: In this study, we used flow cytometry, signaling assays, immunoblotting and confocal immunofluorescence microscopy to investigate the mechanism of the paradoxical signaling activities of high-affinity heparin (native) and low-affinity heparin (latent) conformers of AT in endothelial cells. We discovered that native AT binds to glycosaminoglycans on vascular endothelial cells via its heparin-binding D-helix to induce anti-inflammatory signaling responses by recruiting PKC (protein kinase C)-δ to the plasma membrane and promoting phosphorylation of the Synd-4 cytoplasmic domain at Ser179. By contrast, the binding of latent AT to endothelial cells to a site(s), which is not competed by the native AT, induces a proapoptotic effect by localizing PKC-δ to the perinuclear/nuclear compartment in endothelial cells. Overexpression of a dominant-negative form of PKC-δ resulted in inhibition of anti-inflammatory and proapoptotic signaling activities of both native and latent AT.
CONCLUSIONS: These results indicate that the native and latent conformers of AT may exert their distinct intracellular signaling effects through differentially modulating the subcellular localization of PKC-δ in endothelial cells.

Entities:  

Keywords:  antithrombin; endothelial cells; glycosaminoglycans; heparin; syndecan-4

Mesh:

Substances:

Year:  2020        PMID: 32404004      PMCID: PMC7316612          DOI: 10.1161/ATVBAHA.120.314479

Source DB:  PubMed          Journal:  Arterioscler Thromb Vasc Biol        ISSN: 1079-5642            Impact factor:   8.311


  40 in total

1.  Recombinant human antithrombin III improves survival and attenuates inflammatory responses in baboons lethally challenged with Escherichia coli.

Authors:  M C Minnema; A C Chang; P M Jansen; Y T Lubbers; B M Pratt; B G Whittaker; F B Taylor; C E Hack; B Friedman
Journal:  Blood       Date:  2000-02-15       Impact factor: 22.113

2.  An immunochemical method for quantitative determination of latent antithrombin, the reactive center loop-inserted uncleaved form of antithrombin.

Authors:  M Kjellberg; B Rimac; J Stenflo
Journal:  J Thromb Haemost       Date:  2006-10-18       Impact factor: 5.824

3.  Antithrombin III stimulates prostacyclin production by cultured aortic endothelial cells.

Authors:  T Yamauchi; F Umeda; T Inoguchi; H Nawata
Journal:  Biochem Biophys Res Commun       Date:  1989-09-29       Impact factor: 3.575

4.  Antithrombin up-regulates AMP-activated protein kinase signalling during myocardial ischaemia/reperfusion injury.

Authors:  Yina Ma; Jinli Wang; Junjie Gao; Hui Yang; Yanqing Wang; Chandrashekhara Manithody; Ji Li; Alireza R Rezaie
Journal:  Thromb Haemost       Date:  2014-09-18       Impact factor: 5.249

5.  Proteomic analysis identifies nuclear protein effectors in PKC-delta signaling under high glucose-induced apoptosis in human umbilical vein endothelial cells.

Authors:  Fang Sun; Bo Zhou; Xuebo Lin; Lian Duan
Journal:  Mol Med Rep       Date:  2011-07-04       Impact factor: 2.952

6.  High levels of latent antithrombin in plasma from patients with antithrombin deficiency.

Authors:  María de la Morena-Barrio; Edna Sandoval; Pilar Llamas; Ewa Wypasek; Mara Toderici; José Navarro-Fernández; Agustín Rodríguez-Alen; Nuria Revilla; Raquel López-Gálvez; Antonia Miñano; José Padilla; Belén de la Morena-Barrio; Jorge Cuesta; Javier Corral; Vicente Vicente
Journal:  Thromb Haemost       Date:  2017-02-23       Impact factor: 5.249

Review 7.  Therapeutic rationale for antithrombin III in sepsis.

Authors:  S M Opal
Journal:  Crit Care Med       Date:  2000-09       Impact factor: 7.598

8.  Role of ternary complexes, in which heparin binds both antithrombin and proteinase, in the acceleration of the reactions between antithrombin and thrombin or factor Xa.

Authors:  A Danielsson; E Raub; U Lindahl; I Björk
Journal:  J Biol Chem       Date:  1986-11-25       Impact factor: 5.157

9.  Regulation of tumor necrosis factor receptor-1 and the IKK-NF-kappaB pathway by LDL receptor-related protein explains the antiinflammatory activity of this receptor.

Authors:  Alban Gaultier; Sanja Arandjelovic; Sherry Niessen; Cheryl D Overton; MacRae F Linton; Sergio Fazio; W Marie Campana; Benjamin F Cravatt; Steven L Gonias
Journal:  Blood       Date:  2008-03-27       Impact factor: 22.113

Review 10.  Syndecan-4 signaling at a glance.

Authors:  Arye Elfenbein; Michael Simons
Journal:  J Cell Sci       Date:  2013-08-22       Impact factor: 5.285

View more
  4 in total

1.  A reduction of Syndecan-4 in macrophages promotes atherosclerosis by aggravating the proinflammatory capacity of macrophages.

Authors:  Jiaxin Hu; Ying Zhang; Liaoping Hu; Haiting Chen; Han Wu; Jianzhou Chen; Jun Xie; Biao Xu; Zhonghai Wei
Journal:  J Transl Med       Date:  2022-07-16       Impact factor: 8.440

2.  Extracellular Histones Bind Vascular Glycosaminoglycans and Inhibit the Anti-Inflammatory Function of Antithrombin.

Authors:  Indranil Biswas; Sumith R Panicker; Xiaofeng S Cai; Hemant Giri; Alireza R Rezaie
Journal:  Cell Physiol Biochem       Date:  2021-10-16

3.  Antithrombin protects against Plasmodium falciparum histidine-rich protein II-mediated inflammation and coagulation.

Authors:  Indranil Biswas; Sumith R Panicker; Hemant Giri; Xiaofeng S Cai; Alireza R Rezaie
Journal:  Blood Adv       Date:  2022-02-08

Review 4.  Anticoagulant and signaling functions of antithrombin.

Authors:  Alireza R Rezaie; Hemant Giri
Journal:  J Thromb Haemost       Date:  2020-09-09       Impact factor: 16.036

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.